Dive into a collection of past posts and rediscover timeless content.
One overlooked insurance stock keeps growing, improving profits, and getting cheaper while the market looks elsewhere.
A biotech just delivered the first successful late-stage trial ever run in its category, and got punished for it. This gap won’t last.
Executives at this discount grocery chain bought roughly $8 million of company stock over the past year. Shares still trade well below fair value.
A company built on sleep medicine just landed a cancer approval that could redraw its growth story, with a valuation that still hasn’t caught up to what the pipeline is worth.
The PC cycle is hardly booming. That may be exactly why the market is overlooking what the latest cash numbers are saying.
A diversified wealth platform is growing revenue in double digits, and buying back stock hand over fist, yet trades at a fraction of what comparable US financials command.
The next few weeks bring clinical data, a regulatory date, and a chance to test whether estimates are too low. Find out which catalyst could shift the setup.
After a brutal reset year, adjusted earnings are forecast to jump in tomorrow’s print, driven by delicious growth, while the stock has run 33% this year.
Back-to-school inventory is clean, the balance sheet carries no net debt, and the little brother brand quietly became the bigger business.